Honigman Miller Schwartz and Cohn LLP
01/22/2026 | Press release | Distributed by Public on 01/22/2026 11:40
Press Release | Jan 22, 2026Honigman Represents MetaVia Inc. in Closing of $9.3 Million Underwritten Public Offering
Honigman recently advised MetaVia Inc. (NASDAQ: MTVA), a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases, on its underwritten public offering for gross proceeds of approximately $9.3 million, which includes the full exercise of the underwriter's over-allotment to purchase additional shares and warrants.
The offering included 3,005,574 shares of common stock (or common stock equivalents) as well as 4,508,361 of Series C Warrants and 4,508,361 Series D Warrants priced at a combined offering price of $3.10 per share of common stock and accompanying warrants. If fully exercised for cash, the warrants issued in the offering could garner up to approximately $28 million in future gross proceeds to the company. MetaVia expects to use the proceeds for working capital and general corporate purposes, including to continue the clinical development of DA-1726 for obesity treatment.
The Honigman team was led by Partners Phillip D. Torrence and Joshua W. Damm, with support from Associates Cassandra J. O'Hagan and Kelly Lewis.
Read more here.
Honigman Miller Schwartz and Cohn LLP published this content on January 22, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 22, 2026 at 17:40 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]